CD274 and cancer: (137) developed an Exos-based DDSs (named as cGAMP@dual-anti-Exos) in which anti-PD-L1 and anti-CD40 were all engineered on the surface of Exos for cancer immunotherapy, and the scheme is shown in Figure 5A).